本文選題：復(fù)方鱉甲軟肝片　切入點(diǎn)：恩替卡韋　出處：《中國醫(yī)院藥學(xué)雜志》2015年19期 　論文類型：期刊論文

【摘要】：目的:系統(tǒng)評(píng)價(jià)復(fù)方鱉甲軟肝片聯(lián)合恩替卡韋及單用恩替卡韋對(duì)慢性乙型肝炎血清肝纖維化四項(xiàng)指標(biāo)的影響。方法:計(jì)算機(jī)檢索相關(guān)期刊論文(CNKI)、中文科技期刊數(shù)據(jù)庫(VIP)、萬方數(shù)據(jù)資源系統(tǒng)(WANFANG DATA)、中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(CBM)以及英文數(shù)據(jù)庫PubMed、Embase、Web of Science、the Cochrane Library,檢索自建庫至2015年1月以來復(fù)方鱉甲軟肝片聯(lián)合恩替卡韋與單用恩替卡韋治療慢性乙型肝炎的臨床隨機(jī)對(duì)照試驗(yàn)。按納入和排除標(biāo)準(zhǔn)篩選文獻(xiàn),再進(jìn)一步提取及分析資料,采用RevMan 5.3軟件對(duì)多個(gè)臨床試驗(yàn)結(jié)果的總體效應(yīng)進(jìn)行Meta分析。結(jié)果:共納入7個(gè)臨床隨機(jī)對(duì)照試驗(yàn),共539例患者,觀察組272例,對(duì)照組267例,均為慢性乙型肝炎治療的研究。復(fù)方鱉甲軟肝片聯(lián)合觀察組血清肝纖維化四項(xiàng)指標(biāo)即透明質(zhì)酸(HA),層粘連蛋白(LN),Ⅲ型前膠原蛋白(PCⅢ)、Ⅳ型膠原蛋白(IV-C)水平均較單用恩替卡韋組顯著降低(P0.05)。結(jié)論:復(fù)方鱉甲軟肝片聯(lián)合恩替卡韋能明顯降低慢性乙型肝炎血清肝纖維化指標(biāo),但由于目前研究質(zhì)量偏低,尚需要大量、嚴(yán)格、方法學(xué)質(zhì)量高的隨機(jī)對(duì)照試驗(yàn)進(jìn)一步證實(shí)。
[Abstract]:Objective: to evaluate the effects of compound Biejia Ruangan tablets combined with entecavir and entecavir alone on serum hepatic fibrosis in patients with chronic hepatitis B. methods: to search the Chinese Journal Full-text Database (CNKI), Chinese science and technology, and to evaluate the effects of compound Biejia Ruangan tablets on serum hepatic fibrosis in patients with chronic hepatitis B. The periodical database, Wan-fang data resource system, Chinese Biomedical Literature Database (CBM) and English database, PubMedbase of Science of the Cochrane Library, have been searched to retrieve the self-built database from January 2015 to the date of January 2015. The database is composed of Fufang Biejia Ruanggan tablets combined with Entecavir and single Endi. A randomized controlled clinical trial of Cavir in the treatment of chronic hepatitis B. the literature was screened according to inclusion and exclusion criteria. The data were further extracted and analyzed, and the total effect of multiple clinical trials was analyzed by Meta using RevMan 5.3 software. Results: a total of 539 patients were enrolled in 7 clinical randomized controlled trials, 272 patients in the observation group and 267 in the control group. All of them were treated with chronic hepatitis B. the serum levels of four indexes of hepatic fibrosis in the compound Biejia Ruanggan tablet group, I. e., hyaluronate, laminin (LNN), procollagen type 鈪，

本文編號(hào)：1614518